U.S. markets open in 2 hours 18 minutes

  • S&P Futures

    4,692.25
    +2.00 (+0.04%)
     

  • Dow Futures

    36,279.00
    +64.00 (+0.18%)
     

  • Nasdaq Futures

    16,346.50
    -5.25 (-0.03%)
     

  • Russell 2000 Futures

    2,443.10
    +8.80 (+0.36%)
     

  • Crude Oil

    82.61
    +1.34 (+1.65%)
     

  • Gold

    1,818.70
    +1.90 (+0.10%)
     

  • Silver

    24.35
    +0.20 (+0.82%)
     

  • EUR/USD

    1.1575
    +0.0008 (+0.07%)
     

  • 10-Yr Bond

    1.4530
    0.0000 (0.00%)
     

  • Vix

    16.63
    +1.19 (+7.71%)
     

  • GBP/USD

    1.3507
    +0.0005 (+0.04%)
     

  • USD/JPY

    113.4430
    +0.0430 (+0.04%)
     

  • BTC-USD

    65,950.81
    +4,053.15 (+6.55%)
     

  • CMC Crypto 200

    1,621.20
    +81.18 (+5.27%)
     

  • FTSE 100

    7,299.04
    -4.92 (-0.07%)
     

  • Nikkei 225

    29,507.05
    -104.52 (-0.35%)
     

Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Adicet Bio
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference taking place on November 15-17, 2021.

Details of the events are as follows:

Date: Monday, November 15, 2021
Time: 4:00 pm ET

A live audio webcast of the of the Stifel presentation can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com


Recommended Stories

  • Better Buy After Earnings: Moderna or Novavax?

    Moderna (NASDAQ: MRNA) has outpaced Novavax (NASDAQ: NVAX) in just about every area this year. The company launched its coronavirus vaccine worldwide -- and has generated billions of dollars in revenue and profit. Moderna shares have climbed more than 126% year to date.

  • Kiyosaki: The US stock market is headed for 'giant crash' followed by a new depression — here are the only 3 assets he likes as protection

    "Rich Dad Poor Dad" has made this call before. He's not backing down.

  • With Stocks at All-Time Highs, 3 Stocks to Buy Without Hesitation

    The market is soaring, but this shouldn't scare away investors.

  • 4 No-Brainer Buffett Stocks to Buy With $500 in November

    Perhaps no investor has demonstrated how powerful an ally time can be than Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett. Since taking over as CEO in 1965, the Oracle of Omaha has led Berkshire to an average annual return of 20% on the nose, through 2020. This might not sound like much nominally, but when examined in aggregate through 2021's year-to-date gains, it works out to an increase in Berkshire's Class A shares (BRK.A) of almost 3,500,000%.

  • 'This one is next' — here's why WallStreetBets founder Jaime Rogozinski is tapping Trump's new SPAC as the clear meme trade of the day

    These ideas could be the next ones sent to the moon.

  • 10 Large-Cap Stocks to Buy According to Matthew Tewksbury’s Stevens Capital

    In this article, we discuss the 10 large-cap stocks to buy according to Matthew Tewksbury’s Stevens Capital based on Q2 holdings of the fund. If you want to skip our detailed analysis of Tewksbury’s history, investment philosophy, and hedge fund performance, go directly to 5 Large-Cap Stocks to Buy According to Matthew Tewksbury’s Stevens Capital. […]

  • Here comes the travel boom: Morning Brief

    Top news and what to watch in the markets on Monday, November 8, 2021.

  • 3 Stocks I Never Expect to Sell

    These companies have been firing on all cylinders for a long time, and that's likely to continue.

  • Why ChargePoint Holdings Stock Climbed 24% in October

    Much of the recent interest in the electric vehicle sector was due to anticipation for a new infrastructure bill -- and that's now a reality.

  • 2 ‘Underfollowed’ Cannabis Stocks Gearing up for Gains; Analyst Says ‘Buy’

    Last year, the Democratic Party won a major electoral victory at the upper Federal levels, taking control of the White House and the US Senate, while retaining control of the House of Representatives. Their control of Congress rests on thin margins – but it is a legislative majority, and it held out high hopes of real policy shifts from the Trump Administration. Cannabis investors, especially, were pleased, as the Democrats are seen as far more likely to legalize the substance at the Federal lev

  • Is Ocugen a Buy?

    Despite several face-melting crashes, Ocugen's (NASDAQ: OCGN) stock rose more than 666% this year so far, and it might have further to go, provided that its flagship coronavirus vaccine gets cleared for sales in North America. What will regulators do? The biggest questions facing Ocugen at the moment are which regulators will greenlight its vaccine, and whether any of those potential green lights might actually translate into significant revenue.

  • Pfizer’s Covid Pill Is Shaking Up the Global Recovery Trade

    (Bloomberg) -- Shares tied to reopening trades from casinos to airlines surged in Asia on Monday after Pfizer Inc. said that its Covid-19 pill could reduce hospitalizations and deaths in high-risk patients by 89%. Most Read from BloombergWhere Did All the Public Bathrooms Go?What It Means to Design a Space for ‘Care’COP26 Protests: Inflatable Cows, Megaphones and a RainbowThe Rising Pacific Forces a Native Village to Move. Who Will Pay?‘Airbnb Queen’ Says She’s Caught Up in Platform’s New York F

  • Giant Pension Drops Nikola and Workhorse Stock. It Bought Palantir and Snowflake.

    New Jersey?s state pension exited investments in EV companies Nikola and Workhorse, and bought shares of data-analytics firms Palantir and Snowflake.

  • 5 Cryptocurrencies With a Brighter Future Than Shiba Inu

    Despite SHIB's mammoth 13,200,000% move higher, these digital currencies offer more long-term promise.

  • 10 Best COVID Stocks To Buy Now

    In this article, we discuss the 10 Best COVID Stocks To Buy Now. You can skip our detailed analysis of these Covid stocks and go directly to read the 5 Best COVID Stocks To Buy Now. Covid-19 crushed almost every sector, resulting in the world economy shrinking by 3.2% in 2020. In the initial stages […]

  • Where Will Ocugen Be in 3 Years?

    Over the last three years, Ocugen's (NASDAQ: OCGN) stock has lost 60% of its value, frustrating the small biotech's early investors. This is likely thanks to its externally developed coronavirus vaccine, which might be approved for sale sometime next year. Will its vaccine lift it to new heights by the end of 2024, or is Ocugen's time in the limelight approaching an end now that its competitors are so far ahead?

  • Is Nvidia Stock A Buy? Chip Giant Triggers 8-Week Hold Rule On Metaverse Push

    Nvidia chips power a future of self-driving cars and cloud gaming, while the global semiconductor market is in a supply crunch. Is Nvidia stock a good buy now?

  • Crypto Tesla Tokens Drop 6.8% After Musk Suggests Selling Stock

    (Bloomberg) -- Crypto traders are telling stock traders that Tesla Inc.’s shares will probably fall when Wall Street wakes up Monday. Most Read from BloombergWhere Did All the Public Bathrooms Go?What It Means to Design a Space for ‘Care’COP26 Protests: Inflatable Cows, Megaphones and a RainbowThe Rising Pacific Forces a Native Village to Move. Who Will Pay?‘Airbnb Queen’ Says She’s Caught Up in Platform’s New York FeudOver the weekend, Elon Musk asked his legion of Twitter followers whether he

  • Investing $100,000 in These Dividend Stocks Could Give You Nearly $6,000 in Steady Annual Income

    Many dividend stocks don't have high enough yields to generate significant income. Others have high dividend yields but come with unacceptable levels of risk. If you take one-third of your initial $100,000 and buy shares of AbbVie (NYSE: ABBV), you should be able to count on at least $1,600 in annual income.

  • Wall Street 'permanently changed' by meme stocks, retail trading: star YouTube trader

    The 'meme stock' phenomenon may have been considered 'a fad' some, but its longevity is proof that this is journey "is here to stay," says one prominent retail trader.